Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

133M-1

Sigma-Aldrich

CD33 (PWS44) Mouse Monoclonal Antibody

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41

Source biologique

mouse

Niveau de qualité

100
500

Conjugué

unconjugated

Forme d'anticorps

culture supernatant

Type de produit anticorps

primary antibodies

Clone

PWS44, monoclonal

Description

For In Vitro Diagnostic Use in Select Regions (See Chart)

Forme

buffered aqueous solution

Espèces réactives

human

Conditionnement

vial of 0.1 mL concentrate (133M-14)
vial of 0.5 mL concentrate (133M-15)
bottle of 1.0 mL predilute (133M-17)
vial of 1.0 mL concentrate (133M-16)
bottle of 7.0 mL predilute (133M-18)

Fabricant/nom de marque

Cell Marque

Technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:20-1:80

Isotype

IgG2b

Contrôle

acute myeloid leukemia with monocytic

Conditions d'expédition

wet ice

Température de stockage

2-8°C

Visualisation

membranous

Informations sur le gène

human ... CD33(945)

Description générale

CD33 (gp67, or siglec-3) is a 67 kDa glycosylated transmembrane protein that is a member of the sialic acid-binding immunoglobulin-like lectin (siglec) family. The genomic locus of this protein has been mapped to chromosome 1 9q1 3.1-3.5. In maturing granulocytic cells, there is progressive down-regulation of CD33 from the blast stage to mature neutrophils. However, in monocytes and macrophages/histiocytes, strong expression of CD33 is maintained throughout maturation. Therefore, the positive control tissue should be bone marrow myeloid cells (especially myeloid precursors), liver Kupffer cells, lung alveolar macrophages, or placental syncytiotrophoblasts. Detection of CD33 using monoclonal antibodies has been a critical component in immunophenotyping acute leukemias, particularly acute myeloid leukemias. This anti-CD33 may be particularly advantageous for cases of acute myeloid leukemia, minimally differentiated (AML-M0) and acute monocytic leukemia (AML-M5), in which other paraffin section markers of myeloid differentiation (such as anti-myeloperoxidase) may be negative. However, anti-CD33 staining cannot be used in isolation and must be correlated with other myeloid and lymphoid markers because cases of myeloid antigen-positive acute lymphoblastic leukemia may show bona fide CD33 expression. In characterizing a blast population, this antibody seems to be most useful when the percentage of blasts is high, such as in acute leukemias. It is not a helpful marker in estimating the percentage of blasts, such as in myelodysplastic syndromes or chronic myeloproliferative disorders, because other early granulocytic precursors such as promyelocytes and myelocytes will also stain with anti-CD33. Acute myeloid leukemias that involve extramedullary tissues frequently have monocytic differentiation. A definitive immunophenotype is often difficult to obtain because these cases may be negative or only focally positive for myeloperoxidase, and the currently available monocytic markers (anti-CD68 and anti-lysozyme) have limited specificity. All cases of myeloid sarcoma in this study showed anti-CD33 positivity in the myeloid and monocytic subsets, allowing for easy interpretation. The excellent sensitivity and specificity for myelomonocytic lineage makes this anti-CD33 a useful diagnostic marker for myeloid sarcoma. In addition, this anti-CD33 may be useful in determining CD33 expression on previous paraffin-embedded material if flow cytometry studies were not initially performed in patients with acute leukemia. Analysis of CD33 expression in paraffin-embedded bone marrow biopsy specimens provides another alternative when evaluating acute leukemias.

Qualité


IVD

IVD

IVD

RUO

Forme physique

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Notes préparatoires

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Autres remarques

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Informations légales

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

12 - Non Combustible Liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Kylie D Mason et al.
Blood reviews, 20(2), 71-82 (2005-09-28)
Immunophenotyping of acute myeloid leukemia has controversial implications with regards to prognosis. Many associations have been described between individual antigen expression on myeloid blasts and prognosis, however few are consistent. Markers with a consistent prognostic association that have been demonstrated
Paul R Crocker et al.
Biochemical Society symposium, (69)(69), 83-94 (2003-03-27)
Siglecs are sialic-acid-binding proteins of the Ig superfamily that are involved in cell-cell interactions and signalling. In recent years, several novel siglecs that are highly related to CD33/Siglec-2 have been identified through genomics and functional screens. In addition to their
R C Braylan et al.
Cytometry, 46(1), 23-27 (2001-03-10)
At the ISAC 2000 Congress, the Clinical Cytometry Society organized a meeting of international experts to reach consensus on the minimum number of antibodies required for a full evaluation of hematologic and lymphoid neoplasias. A questionnaire was distributed prior to
Hong Chang et al.
Leukemia research, 28(1), 43-48 (2003-11-25)
We investigated the prognostic relevance of immunophenotype and other clinical pathological features in 379 adult patients with de novo (acute myeloid leukemia) AML diagnosed and treated at our institution during an 8-year period. Acute promyelocytic leukemia (APL) cases were excluded

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique